 |
12 Diseases |  |
3 Trials |
|
3 Trials |  |
248 News |  |
| «1234 |
- | Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Trial completion date: EMERALD: Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants (clinicaltrials.gov) - Jul 26, 2018
P3, N=1153, Active, not recruiting, Sponsor: Janssen R&D Ireland
Trial completion date: Sep 2019 --> Mar 2020
- ||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Trial completion date, IO biomarker: EMERALD: Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants (clinicaltrials.gov) - Apr 26, 2018
P3, N=1154, Active, not recruiting, Sponsor: Janssen R&D Ireland
Trial completion date: Sep 2019 --> Mar 2020 Trial completion date: Mar 2019 --> Sep 2019
- ||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Trial completion date, IO biomarker: EMERALD: Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants (clinicaltrials.gov) - Mar 3, 2018
P3, N=1153, Active, not recruiting, Sponsor: Janssen R&D Ireland
Trial completion date: Mar 2019 --> Sep 2019 Trial completion date: Oct 2019 --> Mar 2019
- ||||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Enrollment closed, Trial completion date, Trial primary completion date, IO biomarker: DIAMOND: A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care (clinicaltrials.gov) - Feb 15, 2018
P3, N=100, Active, not recruiting, Sponsor: Janssen Scientific Affairs, LLC
Trial completion date: Oct 2019 --> Mar 2019 Recruiting --> Active, not recruiting | Trial completion date: Jan 2019 --> Dec 2018 | Trial primary completion date: Jan 2019 --> Dec 2018
- |||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Trial primary completion date, IO biomarker: AMBER: A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects (clinicaltrials.gov) - Oct 10, 2017
P3, N=725, Active, not recruiting, Sponsor: Janssen Sciences Ireland UC
Recruiting --> Active, not recruiting | Trial completion date: Jan 2019 --> Dec 2018 | Trial primary completion date: Jan 2019 --> Dec 2018 Trial primary completion date: Dec 2018 --> Mar 2017
- |||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Trial primary completion date, IO biomarker: EMERALD: Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants (clinicaltrials.gov) - Oct 10, 2017
P3, N=1153, Active, not recruiting, Sponsor: Janssen R&D Ireland
Trial primary completion date: Dec 2018 --> Mar 2017 Trial primary completion date: Dec 2018 --> Feb 2017
- |||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Trial primary completion date, IO biomarker: EMERALD: Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants (clinicaltrials.gov) - Sep 13, 2017
P3, N=1154, Active, not recruiting, Sponsor: Janssen R&D Ireland
Trial primary completion date: Dec 2018 --> Feb 2017 Trial primary completion date: Sep 2017 --> Dec 2018
- |||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Trial primary completion date, IO biomarker: AMBER: A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects (clinicaltrials.gov) - Aug 31, 2017
P3, N=725, Active, not recruiting, Sponsor: Janssen Sciences Ireland UC
Trial primary completion date: Sep 2017 --> Dec 2018 Trial primary completion date: Jul 2017 --> Dec 2018
- |||||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Enrollment open, IO biomarker: DIAMOND: A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care (clinicaltrials.gov) - Aug 15, 2017
P3, N=100, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Trial primary completion date: Jul 2017 --> Dec 2018 Not yet recruiting --> Recruiting
- | Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead, Prezcobix (darunavir/cobicistat) / Gilead, J&J
Trial completion: Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets (clinicaltrials.gov) - Aug 8, 2017
P1, N=27, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||||||||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
IO biomarker: DIAMOND: A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care (clinicaltrials.gov) - Jul 24, 2017
P3, N=100, Not yet recruiting, Sponsor: Janssen Scientific Affairs, LLC
- || Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Enrollment change: A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants (clinicaltrials.gov) - Apr 4, 2017
P1, N=126, Completed, Sponsor: Janssen Sciences Ireland UC
Recruiting --> Completed N=96 --> 126
- |||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Trial primary completion date, IO biomarker: AMBER: A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects (clinicaltrials.gov) - Mar 28, 2017
P3, N=746, Active, not recruiting, Sponsor: Janssen Sciences Ireland UC
N=96 --> 126 Trial primary completion date: Apr 2017 --> Jul 2017
- | Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Trial completion: Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants (clinicaltrials.gov) - Mar 7, 2017
P1, N=30, Completed, Sponsor: Janssen Scientific Affairs, LLC
Trial primary completion date: Apr 2017 --> Jul 2017 Recruiting --> Completed
- Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead, Prezcobix (darunavir/cobicistat) / Gilead, J&J
Enrollment open: Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets (clinicaltrials.gov) - Feb 17, 2017
P1, N=30, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Not yet recruiting --> Recruiting
- Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Enrollment open: Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants (clinicaltrials.gov) - Jan 24, 2017
P1, N=30, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Enrollment closed, IO biomarker: AMBER: A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects (clinicaltrials.gov) - Dec 23, 2016
P3, N=749, Active, not recruiting, Sponsor: Janssen Sciences Ireland UC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead, Prezcobix (darunavir/cobicistat) / Gilead, J&J
New P1 trial: Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets (clinicaltrials.gov) - Dec 15, 2016
P1, N=30, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
New P1 trial: Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants (clinicaltrials.gov) - Dec 6, 2016
P1, N=30, Not yet recruiting, Sponsor: Janssen Scientific Affairs, LLC
- |||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Trial primary completion date, IO biomarker: EMERALD: Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants (clinicaltrials.gov) - Oct 12, 2016
P3, N=1150, Active, not recruiting, Sponsor: Janssen R&D Ireland
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2016 --> Sep 2017
- ||||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Enrollment closed, IO biomarker: EMERALD: Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants (clinicaltrials.gov) - Apr 7, 2016
P3, N=1146, Active, not recruiting, Sponsor: Janssen R&D Ireland
Trial primary completion date: Sep 2016 --> Sep 2017 Recruiting --> Active, not recruiting
- ||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Trial completion: A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants (clinicaltrials.gov) - Mar 8, 2016
P1, N=96, Completed, Sponsor: Janssen Sciences Ireland UC
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Enrollment open: A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants (clinicaltrials.gov) - Dec 3, 2015
P1, N=96, Recruiting, Sponsor: Janssen Sciences Ireland UC
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
New P1 trial: A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants (clinicaltrials.gov) - Oct 22, 2015
P1, N=96, Not yet recruiting, Sponsor: Janssen Sciences Ireland UC
- ||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Trial completion: Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination (clinicaltrials.gov) - Oct 22, 2015
P1, N=72, Completed, Sponsor: Janssen Sciences Ireland UC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Enrollment closed: Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination (clinicaltrials.gov) - Jul 29, 2015
P1, N=72, Active, not recruiting, Sponsor: Janssen Sciences Ireland UC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Enrollment open, IO biomarker: AMBER: A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects (clinicaltrials.gov) - Jul 14, 2015
P3, N=670, Recruiting, Sponsor: Janssen Sciences Ireland UC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
New P1 trial: Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination (clinicaltrials.gov) - Jun 18, 2015
P1, N=72, Recruiting, Sponsor: Janssen Sciences Ireland UC
- ||||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Enrollment change, IO biomarker: EMERALD: Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants (clinicaltrials.gov) - Jun 12, 2015
P3, N=1100, Recruiting, Sponsor: Janssen R&D Ireland
Not yet recruiting --> Recruiting N=600 --> 1100
- |||||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Enrollment open, Enrollment change, Trial primary completion date, IO biomarker: EMERALD: Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants (clinicaltrials.gov) - May 13, 2015
P3, N=600, Recruiting, Sponsor: Janssen R&D Ireland
N=600 --> 1100 Not yet recruiting --> Recruiting | N=420 --> 600 | Trial primary completion date: Jun 2016 --> Sep 2016
- || Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
New P3 trial, IO biomarker: AMBER: A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects (clinicaltrials.gov) - Apr 30, 2015
P3, N=670, Not yet recruiting, Sponsor: Janssen Sciences Ireland UC
- ||||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Enrollment change, IO biomarker: EMERALD: Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants (clinicaltrials.gov) - Jan 12, 2015
P3, N=420, Not yet recruiting, Sponsor: Janssen R&D Ireland
Not yet recruiting --> Recruiting | N=420 --> 600 | Trial primary completion date: Jun 2016 --> Sep 2016 N=660 --> 420
- ||||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Trial initiation date, IO biomarker: EMERALD: Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants (clinicaltrials.gov) - Dec 24, 2014
P3, N=660, Not yet recruiting, Sponsor: Janssen R&D Ireland
N=660 --> 420 Initiation date: Nov 2014 --> Feb 2015
- |||||||||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
New P3 trial, IO biomarker: EMERALD: Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants (clinicaltrials.gov) - Oct 22, 2014
P3, N=660, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- |||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
Trial completion: D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults (clinicaltrials.gov) - Feb 26, 2014
P2, N=155, Completed, Sponsor: Gilead Sciences
Initiation date: Nov 2014 --> Feb 2015 Active, not recruiting --> Completed
- ||||| Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
New P2 trial: D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults (clinicaltrials.gov) - Mar 27, 2012
P2, N=155, Completed, Sponsor: Gilead Sciences